Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping
作者:Zhimin Zhang、Lili Gu、Beibei Wang、Wenhai Huang、Yanmin Zhang、Zhen Ma、Shenxin Zeng、Zhengrong Shen
DOI:10.1080/14756366.2019.1587417
日期:2019.1.1
in the treatment of many human disorders such as cancer, inflammation, obesity, and cardiovascular disease. Recently, the discovery of novel BRD4 inhibitors has garnered substantial interest. Starting from scaffold hopping of the reported compound dihydroquinazolinone (PFI-1), a series of coumarin derivatives were designed and synthesised as a new chemotype of BRD4 inhibitors. Interestingly, the representative
抽象的 在许多人类疾病如癌症,炎症,肥胖症和心血管疾病的治疗中,溴结构域和末端外(BET)的溴结构域,特别是BRD4,已被确定为有希望的治疗靶标。最近,新型BRD4抑制剂的发现引起了人们的极大兴趣。从报道的化合物二氢喹唑啉酮(PFI-1)的支架跳跃开始,设计并合成了一系列香豆素衍生物,作为BRD4抑制剂的新化学型。有趣的是,代表性化合物13表现出强大的BRD4结合亲和力和细胞增殖抑制活性,尤其是表现出良好的PK分布以及较高的口服生物利用度(F = 49.38%)和代谢稳定性(T 1/2 = 4.2 h),有意义地使其成为进一步药物开发的有前途的先导化合物。